Urovant Sciences Ltd (UROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,295 | -37,074 | -17,979 | -8,528 | -3,615 |
| Depreciation Amortization | 40 | 12 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 4,209 | 817 | 400 | 18 | 114 |
| Other Working Capital | 9,908 | -227 | 2,260 | 1,513 | 1,986 |
| Other Operating Activity | -3,623 | 2,386 | 2,108 | 1,834 | 914 |
| Operating Cash Flow | $-20,761 | $-34,086 | $-13,211 | $-5,163 | $-601 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -115 | -522 | N/A | N/A | N/A |
| Investing Cash Flow | $-115 | $-522 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 17,935 | 37,035 | 16,035 | 5,035 | 35 |
| Financing Cash Flow | $17,935 | $37,035 | $16,035 | $5,035 | $35 |
| Beginning Cash Position | 7,194 | 4,767 | 4,767 | 4,767 | 4,768 |
| End Cash Position | 4,253 | 7,194 | 7,591 | 4,639 | 4,202 |
| Net Cash Flow | $-2,941 | $2,427 | $2,824 | $-128 | $-566 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,761 | -34,086 | -13,211 | -5,163 | -601 |
| Capital Expenditure | -115 | -522 | N/A | N/A | N/A |
| Free Cash Flow | -20,876 | -34,608 | -13,211 | -5,163 | -601 |